Novartis bets on autoimmune BiTEs through $7.8bn Abogen deal
Novartis has become the latest big pharma player to bet on the bispecific T-cell engager (BiTE) modality by inking a …
Post
-
-
Magazine: Keep it cool
Pharma is being pulled in every direction at once: more complex, more connected, more uncertain. Yet the industry keeps moving, …
-
Drug delivery’s next bottleneck isn’t innovation, it’s industrial capacity
New biologics, expanding indications, and rapid growth in GLP-1 therapies are bringing effective treatments to unprecedented numbers of patients. Yet …
-
Sanofi and Regeneron expand immunology partnership to the tune of $8bn
Having already brought one of the most successful drugs in the world to market, Sanofi and Regeneron are broadening their …
-
Varda pockets $251m to back space-based pharma processing mission
Varda Space Industries has banked $251m in a Series D financing to scale its in-space pharmaceutical processing operations, as the …
-
Varda pockets $251m to back space-based pharma processing mission
Varda Space Industries has banked $251m in a Series D financing to scale its in-space pharmaceutical processing operations, as the …
-
Bristol Myers Squibb secures expanded US approval for Camzyos
The US Food and Drug Administration (FDA) has expanded the approved indication for Bristol Myers Squibb’s (BMS) Camzyos (mavacamten) to …
-
BioMarin and Profluent partner on AI-designed enzyme therapies
BioMarin Pharmaceutical has entered a research collaboration with Profluent to design and optimise novel enzyme therapies for its drug development …
-
EASD 2026: Tirzepatide outperforms semaglutide in real-world type 2 diabetes analysis
This year at the European Association for the Study of Diabetes (EASD) Annual Meeting, real-world data were presented comparing Eli …
-
Leading CDMO to attend CPHI Milan 2026 in Italy
Globally renowned contract development and manufacturing organisation (CDMO) Piramal Pharma Solutions (PPS) will showcase its expertise at the upcoming CPHI …
-
EASD 2026: CagriSema weight loss holds at submaximal doses in REDEFINE-1 analysis
On 29 September, at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, …
-
Atossa plans shareholder stake in potential PRV proceeds
Atossa Therapeutics has put in place a plan that would give its shareholders a share of any proceeds from the …
-
OBIO marks $704m funding milestone for Canadian health tech ventures
Life sciences and technology companies supported by the Ontario Bioscience Innovation Organization’s (OBIO) Capital Access Advisory Program (CAAP) have collectively …
-
Kyowa Kirin, Knight agree Latin American distribution deal for mogamulizumab
Kyowa Kirin’s wholly owned subsidiary Kyowa Kirin International has signed an exclusive distribution agreement with Knight Therapeutics for Poteligeo (mogamulizumab) …
-
EASD 2026: Orforglipron shows an efficacy edge over oral semaglutide in T2D
This year at the European Association for the Study of Diabetes (EASD) Annual Meeting, an indirect treatment comparison evaluated Eli …
